Enhancement of skin permeation and anti-inflammatory effect of indomethacin using nanoemulsuion

Letters in Drug Design and Discovery

Volumn 9, Issue 4, 2012, Pages 436-446

  Barakat, Nahla ^a   Fouad, Ehab ^a   Elmedany, Azza ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Anti inflammatory effect; Indomethacin; Nanoemulsion; Permeability coefficient; Surfactant:co surfactant mixture

Indexed keywords

INDOMETACIN; MYRISTIC ACID ISOPROPYL ESTER; OLEIC ACID; PENETRATION ENHANCING AGENT; SOYBEAN OIL; SURFACTANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; EX VIVO STUDY; HYDROPHILICITY; IN VITRO STUDY; LIPOPHILICITY; MALE; MISCIBILITY; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PAW EDEMA; PRIORITY JOURNAL; RABBIT; RAT; STRATUM CORNEUM; TRANSMISSION ELECTRON MICROSCOPY; VISCOSITY;

EID: 84860589679     PISSN: 15701808     EISSN: 1875628X     Source Type: Journal    
DOI: 10.2174/157018012799859891     Document Type: Article

References (55)

1. Kreilgaard M. Influence of NEs on cutaneous drug delivery. Adv Drug Deliv Rev. 2002, 54 (Suppl. 1), S77-S98. (Pubitemid 35379956)
2. Tenjarla S. NEs: an overview and pharmaceutical applications. Crit Rev Ther Drug Carrier Syst. 1999, 16, 461-521.
3. Gasco MR. NEs in the Pharmaceutical Field. In: Perspectives and Applications, Industrial Applications of NEs. Marcel Dekker Inc., New York, 1997, pp. 97-122.
4. Lawrence MJ.; Rees GD. NE-based media as novel drug delivery systems. Adv Drug Deliv Rev. 2000, 45, 89-121.
5. Sintov AC.; Shapiro L. New NE vehicle facilitates percutaneous penetration in vitro and cutaneous drug bioavailability in vivo. J Controll Release. 2004, 95, 173-183. (Pubitemid 38230033)
6. Gasco MR.; Gallarate M.; Trotta M.; Bauchiero L.; Gremmo E.; Chiappero O. NEs as topical delivery vehicles: ocular administration of timolol. J Pharm Biochem Anal. 1989, 7 (4), 433-439. (Pubitemid 19156054)
7. Zhu W.; Yu A.; Wang W.; Dong R.; Wu J.; Zhaia G. Formulation design of NE for dermal delivery of penciclovir. Int J Pharm. 2008, 360, 184-190.
8. Kuminek G.; Kratz JM.; Ribeiro R.; Kelmann RJ.; de Araújo BV.; Teixeira HF.; Simões CMO.; Koester LS. Pharmacokinetic study of a carbamazepine nanoemulsion in beagle dogs. Int J Pharm. 2009, 378, 146-148.
9. Djordjevic L.; Primorac M.; Stupar M.; Krajisnik D. Characterization of caprylocaproyl macrogolglycerides based NE drug delivery vehicles for an amphiphilic drug. Int J Pharm. 2004, 271, 11-19. (Pubitemid 38210080)
10. Lee J.; Lee Y.; Kim J.; Yoon M.; Choi YW. Formulation of NE systems for transdermal delivery of aceclofenac. Arch. Pharm. Res. 2005, 28 (9), 1097-1102. (Pubitemid 41426859)
11. Madhusudhan B.; Rambhau D.; Apte SS.; Gopinath D. 1-Oalkylglycerol stabilized carbamazepine intravenous o/w nanoemulsions for drug targeting in mice. J Drug Target. 2007, 15, 154-161. (Pubitemid 46957702)
12. Cevc G.; Vierl U. Nanotechnology and the transdermal route: A state of the art review and critical appraisal. J Controll Release. 2010, 141 (3), 277-299.
13. Monteiro-Riviere NA.; Inman AD.; Riviere JE.; McNeill SC.; Francoeur ML. Topical penetration of piroxicam is dependent on the distribution of the local cutaneous vasculature. Pharm Res. 1993, 10, 1326-1331. (Pubitemid 23261834)
14. Singh P. Roberts MS. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. J Pharmacol Exp Ther. 1994, 268, 144-151. (Pubitemid 24039081)
15. El-Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil NE. Int J Pharm. 2008, 355, 285-292.
16. Shakeel F.; Baboota S.; Ahuja A.; Ali J.; Aqil M.; Shafiq S. Nanoemulsions as vehicles fro transdermal delivery of aceclofenac. AAPS PharmSciTech. 2007, 8(4), article 104 (http://www.aapspharmscitech.org).
17. Nandi I.; Bari M.; Joshi H. Study of Isopropyl Myristate NE Systems Containing Cyclo-dextrins to improve the Solubility of 2 Model Hydrophobic Drugs. AAPS PharmSciTech. 2003, 4(1), Article 10. (http://www.pharmscitech.org).
18. Burapapadh K.; Kumpugdee-Vollrath M.; Chantasart D.; Sriamornsak P. Fabrication of pectin-based nanoemulsions loaded with itraconazole for pharmaceutical application. Carbohydrate Polymers. 2010, 82 (2), 384-393.
19. Peltola S.; Saarinen-Savolanien P.; Kiesvaara J.; Suhonen TM.; Urtti A. NE for topical delivery of estradiol. Int J Pharm. 2003, 254, 99-107.
20. Rhee YS.; Choi JG.; Park ES.; Chi SC. Transdermal delivery of ketoprofen using NEs. Int J Pharm. 2001, 228, 161-170 .
21. Delgado-Charro MB.; Iglesias-Vilas G.; Blanco-Měndez J.; Lǒpez-Quintela MA.; Marty JP.; Guy RH. Delivery of a hydrophilic solute through the skin from novel NE systems. Eur J Pharm biopharm. 1997, 43, 37-42. (Pubitemid 28298808)
22. Baroli,B.; Lopez-Quintela MA.; Delgado-Charro MB.; Fadda AM.; Blanco-Mendez J. NEs for topical delivery of 8-methoxsalen. J Controll Release. 2000, 69, 209-218.
23. Zhao X.; Liu JP.; Zhang X.; Li Y. Enhancement of transdermal delivery of theophylline using NE vehicle. Int J Pharm. 2006, 327, 58-64. (Pubitemid 44667336)
24. Walters KA. Penetration enhancers and their use in transdermal therapeutic systems. In: Hadgraft J.; Guy RH. eds. Transdermal Drug Delivery, Developmental Issues and Research Initiatives. New York, NY: Marcel Dekker; 1989,197-246.
25. Tadros TF. Future developments in cosmetic formulations. Int J Cosmet Sci. 1992, 14, 93-111.
26. Pattarino F.; Marengo E.; Gasco MR. Experimental design and partial least squares in the study of complex mixtures: NEs as drug carriers. Int J Pharm. 1993, 91, 157-165. (Pubitemid 23159819)
27. Ghosh PK.; Majithiya RJ.; Umrethia ML.; Murthy RSR. Design and Development of NE Drug Delivery System of Acyclovir for Improvement of Oral Bioavailability. AAPS PharmSciTech. 2006, 7(3), Article 77. (http://www. aapspharmscitech.org).
28. Gannu R.; Palem CR.; Yamsani VV.; Yamsani SK.; Yamsani MR. Enhanced bioavailability of lacidipine via NE based transdermal gels: Formulation optimization, ex vivo and in vivo characterization. Int J Pharm. 2010, 388, 231-241.
29. Celesti L.; Murratzu C.; Valoti M.; Sgaragli P, Corti P. The singlepass perfused rabbit ear as a model for studying percutaneous absorption of clonazepam. I. General characteristics. Methods Find. Exp Clin Pharmacol. 1992, 14, 701-709. (Pubitemid 23057190)
30. Yuan Y.; Li S-M.; Mo F-K.; Zhong D-F. Investigation of NE system for transdermal delivery of meloxicam. In.t J. Pharm. 2006, 321, 117-123. (Pubitemid 44247427)
31. Touitou E.; Dayan N.; Bergelson L.; Godin B.; Eliaz M. Ethosomes-novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. J Controll Release. 2000, 65, 403-418. (Pubitemid 30122942)
32. Al-Swayeh, PK.; Clifford RH.; del Soldato P.; Moore PK. A comparison of the anti-inflammatory and antinociceptive activity of nitroaspirin and aspirin. Br J Pharmacol. 1999, 129, 343-350.
33. Winter CA. Anti-inflammatory testing methods: comparative evaluation of indomethacin and other agents. Int Symp Nonst Antiinflamm Drugs 1965, 82, 190-202.
34. Subramanian N.; Ray S.; Ghosal SK.; Bhadra R.; Moulik SP. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm. 2004, 66, 227-243.
35. Kreilgaard M.; Pedersen EJ.; Jaroszewski JW. NMR characterization and transdermal drug delivery potential of NE systems. J Controll Release. 2000, 69, 421-433.
36. Tomšič M.; Podlogar F.; Gašperlin M.; Bešter-Rogač M.; Jamnik A. Water-Tween 40®/Imwitor 308®-isopropyl myristate NE as delivery systems for ketoprofen: Small-angle X-ray scattering study. Int J Pharm. 2006, 327(1-2), 170-177. (Pubitemid 44667341)
37. Changez M.; Varshney M.; Chander J.; Dinda AK. Effect of the composition of lecithin/n-propanol/isopropyl myristate/water NEs on barrier properties of mice skin for transdermal permeation of tetracaine hydrochloride: In vitro. Colloids and Surfaces B: Biointerfaces 2006, 50, 18-25. (Pubitemid 43794900)
38. Lee PJ.; Langer R.; Shastri VP. Novel NE enhancer formulation for simultaneous transdermal delivery of hydrophilic and drugs. Pharm Res. 2003, 20, 264-269. (Pubitemid 36269734)
39. Takahashi K.; Tamagawa S.; katagi T.; Yoshitomi H.; Kamada A.; Rytting JH.; Mizuno N. In vitro transport of sodium diclofenac across rat abdominal skin: effect of selection of oleaginous component and the addition of alcohols to the vehicle. Chem Pharm Bull. 1991, 39, 154-158.
40. Li H.; PanWS.; Li JY. Preparation, evaluation, and NMR characterization of vinpocetine NE for transdermal delivery. Drug Dev Ind. Pharm. 2004a, 30, 657-66.
41. Li H.; PanWS.; Wu Z.; Li JY.; Xia LX. Optimization of NE containing vinpocetine and its physicochemical properties. Yao Xue Xue Bao 2004b, 39, 681-685. (Pubitemid 40081824)
42. Barthélémy P.; Farah N.; Laforet JP. Transcutol-product profile. Product Information. Gattefossé, 1995, p. 1-10.
43. Craig DQM.; Barker SA.; Banning D.; Booth SW. An investigation into the mechanism of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm. 1995, 114, 103-110. (Pubitemid 24377034)
44. Huang YB.; Wu PC.; Ko HM.; Tsai YH. Cardamon oil as a skin permeation enhancer for indomethacin, piroxicam and diclofenac. Int J Pharm. 1995, 126, 11-17.
45. Zheng WW.; Zhao L.; Wei YM.; Ye Y.; Xiao SH. Preparation and the in vitro evaluation of nanoemulsion system for the transdermal delivery of granisetron hydrochloride. Chem Pharm Bull. 2010, 58 (8), 1015-1019.
46. Gasco MR.; Gallarate M.; Pattarino F. In vitro permeation of azelaic acid from viscosized NE. Int J Pharm. 1991, 69, 193-196.
47. Mei ZN.; Chen HB.; Weng T.; Yang YJ.; Yang X. Solid lipid nanoparticle and NE for topical delivery of triptolide. Eur J Pharm Biopharm. 2008, 56, 189-196.
48. Chang XL.; Chen HB.; Zhao XZ.; Gao ZH.; Xu HB.; Yang XL. High performance liquid chromatography determination of triptolide in vitro permeation studies. Anal Chim Acta 2005, 534, 215-221.
49. Changez M.; Chander J.; Dinda AK. Transdermal permeation of tetracaine hydrochloride by lecithin NE: in vivo. Colloids Surf. B: Biointerfaces. 2006a, 48, 58-66.
50. Chen H.; Chang X.; Du D.; Li J.; Xu H., Yang X. NE-based hydrogel formulation of ibuprofen for topical delivery. Int J Pharm. 2006, 315, 52-58. (Pubitemid 43674110)
51. Barry BW. Mode of action of penetration enhancers in human skin. J Controll Release. 1987, 6, 85-97. (Pubitemid 18017724)
52. Artus IM.; Nicoli S.; Colombo P.; Bettini R.; Sacchi A.; Santi P. Effect of chemical enhancers and iontophoresis on thiocolchicoside permeation across rabbit and human skin in vitro. J Pharm Sci. 2004, 93, 2431-2438. (Pubitemid 39319427)
53. Winter CA.; Risley EA.; Nuss GW. Carrageenan induced edema in hind paw of the rat as an assay fro inflammatory drugs. Proc Soc Exp Biol Med. 1962, 111, 544-547.
54. Shakeel F.; Ramadan W.; Ahmed MA. Investigation of true nanoemulsions for transdermal potential of indomethacin: Characterization rheological characteristics and ex vivo skin permeation studies. J Drug Target. 2009, 17, 435-441.
55. Zhu XL.; Li GF.; Zeng K.; Cheng ZL. Preparation of lidocaine nanoemulsion and its transdermal absorption by rat skin ex vivo]. Fang Yi Ke Da Xue Xue Bao. 2010, 30 (3), 451-4544.